Combining extracorporeal life support and cell therapy in critical illness: mesenchymal stem cell therapy and extracorporeal membrane oxygenation in the Acute Respiratory Distress syndrome

2021 ◽  
Author(s):  
◽  
Jonathan Millar
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Stem Cell ◽  
Critical Illness ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Extracorporeal Membrane Oxygenation ◽  
Distress Syndrome ◽  
Life Support ◽  
Extracorporeal Life Support ◽  
Mesenchymal Stem Cell Therapy

scholarly journals A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal stem cell therapy

2020 ◽  
Vol 24 (6) ◽  
Author(s):  
David Nugraha ◽  
Nabila Ananda Kloping ◽  
Resti Yudhawati ◽  
Azham Purwandhono ◽  
Hanik Badriyah Hidayati
Keyword(s):  
Stem Cells ◽  
Acute Respiratory Distress Syndrome ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Mesenchymal Stem Cell Therapy ◽  
A Current

Indonesia has been fighting the COVID-19 pandemic since the beginning of March 2020, and it doesn’t look that the situation is getting better any soon. Besides the country’s current strategies to minimize the rising mortality rate, a novel therapeutic intervention is required. After a thorough search in several databases, we found stem cells to be a likely candidate. Regardless of the general use of stem cells, studies showed positive results regarding the efficacy of using these in lung injuries. Especially, mesenchymal stem cells (MSCs) are known for their easy accessibility and their diverse mechanisms of action, including MSCs immunomodulatory antiviral effect, and its ability to improve lung function. Moreover, some researches perceived these components to be applicable in COVID-19 patients with end stage acute respiratory distress syndrome (ARDS). While randomized clinical trials are still in progress, many case reports show MSCs to be an advantageous alternative to suppress the cytokine storm and help regulate the immune system. This review summarizes the common functions of MSCs and highlights its therapeutic assets to fully tackle this global pandemic. Key word: Mesenchymal Stem Cells; Cell Therapy; COVID-19; SARS-CoV-2; ARDS Abbreviations: COVID-19 – Coronavirus Disease; MSC – Mesenchymal Stem Cell; ARDS – Acute Respiratory Distress Syndrome Citation: Nugraha D, Kloping NA, Yudhawati R, Purwandhono A, Hidayati HB. A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal stem cell therapy. Anaesth. pain intensive care 2020;24(6):--- Received: , Reviewed: , Revised: , Accepted:

scholarly journals The Role of Extracorporeal Membrane Oxygenation on Acute Respiratory Distress Syndrome

2021 ◽  
Vol 5 (10) ◽  
pp. 953-960
Author(s):  
Dini Ardiyani ◽  
Zen Ahmad
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Lung Injury ◽  
Extracorporeal Membrane Oxygenation ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Life Support ◽  
Extracorporeal Life Support ◽  
Lung Protective Ventilation ◽  
Membrane Oxygenation

Acute lung injury and acute respiratory distress syndrome are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Extracorporeal membrane oxygenation is a form of extracorporeal life support where an external artificial circulator carries venous blood from the patient to a gas exchange device (oxygenator) where blood becomes enriched with oxygen and has carbon dioxide removed. This blood then re-enters the patients circulation. The potential advantages of ECMO over conventional manajement may extend beyond its role in supporting patients with ARDS. ECMO may facilitate and enhance the application of lung-protective ventilation by minimizing ventilator-induced lung injury.

scholarly journals Fulminant Mycoplasma Infection Requiring ECMO in a Previously Healthy Child: Case Report and Review

2017 ◽  
Vol 07 (02) ◽  
pp. 106-109 ◽  
Author(s):  
Janet Hume ◽  
Marie Steiner ◽  
Gwenyth Fischer ◽  
Catherine Heith
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Case Report ◽  
Extracorporeal Membrane Oxygenation ◽  
Distress Syndrome ◽  
Life Support ◽  
Extracorporeal Life Support ◽  
Mycoplasma Infection ◽  
Common Cause ◽  
Extracorporeal Life Support Organization ◽  
Support Organization

Abstract Mycoplasma pneumoniae is a common cause of pneumonia and rarely requires hospitalization. We present a case of a 12-year-old girl who developed acute respiratory distress syndrome requiring extracorporeal membrane oxygenation (ECMO). Eight cases of Mycoplasma infection requiring ECMO reported to the Extracorporeal Life Support Organization and 16 cases reported in the literature are summarized with 72.7% survival cumulatively.

scholarly journals Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

2020 ◽  
Vol 11 (10) ◽  
pp. 707-722 ◽  
Author(s):  
Hua Qin ◽  
Andong Zhao
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Cell Damage ◽  
Paracrine Factors ◽  
Mortality And Morbidity ◽  
Mesenchymal Stem Cell Therapy

Abstract The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS.

scholarly journals The Role of Extracorporeal Membrane Oxygenation on Acute Respiratory Distress Syndrome

2021 ◽  
Vol 5 (4) ◽  
pp. 890-897
Author(s):  
Dini Ardiyani ◽  
Zen Ahmad
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Lung Injury ◽  
Extracorporeal Membrane Oxygenation ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Life Support ◽  
Extracorporeal Life Support ◽  
Lung Protective Ventilation ◽  
Membrane Oxygenation

Acute lung injury and acute respiratory distress syndrome are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Extracorporeal membrane oxygenation is a form of extracorporeal life support where an external artificial circulator carries venous blood from the patient to a gas exchange device (oxygenator) where blood becomes enriched with oxygen and has carbon dioxide removed. This blood then re-enters the patients circulation. The potential advantages of ECMO over conventional manajement may extend beyond its role in supporting patients with ARDS. ECMO may facilitate and enhance the application of lung-protective ventilation by minimizing ventilator-induced lung injury.

Sign in / Sign up

Export Citation Format

Share Document